hepatitis C hepatitis C

Hepatitis C virus, via transmission electron microscopy. (The actual viral diameter is around 22 nm.) Doctors say the recent FDA approval of Mavyret, a less expensive drug for treating the virus, may make it easier for more insurers and correctional facilities to expand treatment. James Cavallini/Science Source hide caption

toggle caption
James Cavallini/Science Source

Vicki Reid, right, holds a likeness of John Martin, who was then CEO of the pharmaceutical company Gilead Sciences. Reid and others were protesting high drug prices in front of the conference on retroviruses and opportunistic infections — a meeting held at the World Congress Center in Atlanta in March 2013. John Amis/AP Images for AIDS Healthcare Foundation hide caption

toggle caption
John Amis/AP Images for AIDS Healthcare Foundation

As Cost Of U.S. Health Care Skyrockets, So Does Pay Of Health Care CEOs

  • Download
  • <iframe src="https://www.npr.org/player/embed/539518682/539576211" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Indiana State Health Commissioner Dr. Jerome Adams is President Trump's nominee for U.S. Surgeon General. Darron Cummings/AP hide caption

toggle caption
Darron Cummings/AP

Used syringes rest in a pile at a needle exchange clinic in St. Johnsbury, Vt. The CDC says needle exchanges like this one, where users can obtain clean needles, help reduce the rates of death and transmission among those suffering from hepatitis C. Spencer Platt/Getty Images hide caption

toggle caption
Spencer Platt/Getty Images

In two recent clinical trials of Harvoni and Sovaldi in the treatment of young people between the ages of 12 and 17, the drugs eliminated all traces of the hepatitis C virus in 97 to 100 percent of patients, generally in 12 weeks. Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

Gilead Sciences' Harvoni can cure hepatitis C, but the drug costs a fortune. Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

Army Specialist Jim McGough with members of his unit in 1971. Then 19, he was photographed by a columnist from The Des Moines Register. Gordon Gammack/The Des Moines Register hide caption

toggle caption
Gordon Gammack/The Des Moines Register

New drugs like Harvoni effectively cure hepatitis C, but they haven't yet been approved for use in children. Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

Harvoni can cure hepatitis C, but the drug costs a fortune. Are loans to patients the answer? Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

A 12-week regimen of Harvoni is 90 percent effective in curing an infection with hepatitis C, doctors say. It also costs about $95,000. Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Baltimore Sun/TNS via Getty Images

States Deny Pricey Hepatitis C Drugs To Most Medicaid Patients

  • Download
  • <iframe src="https://www.npr.org/player/embed/460086615/461206268" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A recent analysis by the Kaiser Family Foundation finds that Medicare recipients taking Revlimid for cancer could end up paying, on average, $11,538 out of pocket for the drug in 2016, even if the medicine is covered by their Medicare Part D plan. Carmine Galasso/MCT/Landov hide caption

toggle caption
Carmine Galasso/MCT/Landov

Retired California school teacher Mikkel Lawrence sits with his cat, Max. Lawrence has hepatitis C and has struggled to afford the medicine he needs to treat it. April Dembosky/KQED hide caption

toggle caption
April Dembosky/KQED

Austin, Indiana's needle exchange program is open for business this week, but health workers worry the program will be tough to quickly replicate in other counties. Darron Cummings/AP hide caption

toggle caption
Darron Cummings/AP

Indiana Struggles To Control HIV Outbreak Linked To Injected Drug Use

  • Download
  • <iframe src="https://www.npr.org/player/embed/403474785/403474795" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Volunteer Patrick Pezzati searches yards in Turners Falls, Mass., for discarded heroin needles. Karen Brown/WFCR hide caption

toggle caption
Karen Brown/WFCR

A Rural Police Chief Asks Citizens To Help Pick Up Used Syringes

  • Download
  • <iframe src="https://www.npr.org/player/embed/401722597/402856156" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Volunteers search for needles and other drug paraphernalia along Church Street in Austin, Ind., in April. The region has recorded 142 new HIV cases since December, according to the state, in an outbreak tied to injected-opioid use. Seth Herald/Nurphoto/Corbis hide caption

toggle caption
Seth Herald/Nurphoto/Corbis

CDC Warns More HIV, Hepatitis C Outbreaks Likely Among Drug Users

  • Download
  • <iframe src="https://www.npr.org/player/embed/401968600/402035073" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The hepatitis C medication Sovaldi, from Gilead Sciences, costs $1,000 per pill. It's just one of the new medications introduced in the past year that can cure the disease within weeks or months. Courtesy of Gilead Sciences via AP hide caption

toggle caption
Courtesy of Gilead Sciences via AP

Costly Hepatitis C Drugs Threaten To Bust Prison Budgets

  • Download
  • <iframe src="https://www.npr.org/player/embed/372721256/372837243" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The newly approved Harvoni tablets bring several advances to the fight against hepatitis C, but they also have a steep price tag, reported at $1,125 for a single dose. Gilead Sciences hide caption

toggle caption
Gilead Sciences